Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine
Wells, B.G.; Evans, R.L.; Ereshefsky, L.; Antal, E.J.; Lobeck, F.; Rawls, W.N.; Hamann, G.; Grimmig, J.; Smith, R.B.
Journal of Clinical Psychiatry 49(10): 394-399
1988
ISSN/ISBN: 0160-6689 PMID: 3049560 Document Number: 322278
Clinical outcome and adverse effects associated with concurrent alprazolam and imipramine administration were studied in 29 patients with major depressive disorder who completed a 6-week trial in which they served as their own controls. Alprazolam was added on Day 8 in gradually escalating, then gradually tapering dosages while imipramine dosages remained unchanged. Significant decreases were observed in scores on the Hamilton Rating Scales for Depression and Anxiety at all later evaluation days with Day 8 as baseline. The mean total Symptom and Side Effects score decreased significantly from Day 8 to Day 22 when alprazolam doses were 1 mg q.i.d. For most side effects, total number of reports remained constant or decreased from Day 1 to later evaluation days. Standing diastolic blood pressures were significantly lower on Day 22 than on Day 1. No significant relationship was found between any rating scale score and plasma concentration data.